Plutux
$5.37
+0.47%
2026-09-04 11:39:19 EDT+$0.02
Atención médica
Médica - Productos farmacéuticos
NASDAQ
Negociación activa

SCYNEXIS, Inc. es una empresa de biotecnología que se dedica al desarrollo de un nuevo antifúngico triterpenoide oral e intravenoso para el ...

Evolución del precio

$5.37
+0.47%+$0.02
Máximo
Mínimo
Máx. 52s-48.8%
Vol. rel.
Intervalo
Rango56m
VolumenSMA5SMA10
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, with a primary focus on anti-infective therapies. The company was founded on November 4, 1999, by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph ...SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, with a primary focus on anti-infective therapies. The company was founded on November 4, 1999, by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill, and is headquartered in Jersey City, New Jersey. SCYNEXIS became a public company in May 2014. SCYNEXIS is best known for its lead product, ibrexafungerp (brand name Brexafemme), a novel oral and intravenous triterpenoid antifungal for the treatment of vulvovaginal candidiasis (VVC), a common fungal infection. The company also develops treatments for invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Its pipeline targets underlying biology of severe rare diseases, with a focus on difficult-to-treat and drug-resistant infections. As of the latest data, SCYNEXIS has approximately 18 full-time employees. The company is led by President and CEO Dr. David Angulo, who assumed the role in January 2023. Other key executives include Scott Sukenick (Chief Legal Officer) and Ivor Macleod (Chief Financial Officer). The board is chaired by Mr. Macdonald, who joined in 2014. Financially, SCYNEXIS is a small-cap company with a market capitalization of around $30 million as of the most recent data. The company has experienced losses typical of clinical-stage biotech, with a negative net profit margin and negative cash flow from operations in the trailing twelve months. However, it maintains a strong liquidity position with a current ratio of 9.65 and no significant debt, with cash per share of $4.57. SCYNEXIS's revenue per share is $1.625, indicating some product revenue from Brexafemme, but overall expenses exceed revenue, leading to a net loss. The company's research and development expenses are about 136.6% of revenue, reflecting heavy investment in its pipeline. Administrative expenses are moderate at 81.1% of revenue. The company's stock price has ranged from $3.53 to $10.48 over the past year, with a beta of 1.1, suggesting higher volatility than the market. SCYNEXIS intends to continue developing its antifungal portfolio and exploring new indications for ibrexafungerp, as well as advancing other early-stage assets for rare diseases.
Fundación
1999
Empleados
18
CEO
David Angulo
Nombre completo
SCYNEXIS, Inc.
Sector
Atención médica
Industria
Médica - Productos farmacéuticos
ROE
-21.10%
Capitalización
$0.05B
Ratio corriente
9.65
WACC
9.58%
ROIC
-19.69%

Información de contacto

201 884 5485
1 Evertrust Plaza, Jersey City, NJ 07302-6548

Acciones relacionadasMedical - Pharmaceuticals

Ver todas las acciones de EE. UU.

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

© Plutux Technology Limited 2026